ReviewCureus2025
A Narrative Review of New Emerging Urological Interventions for Benign Prostatic Hyperplasia: HoLEP, Rezum, and Aquablation.
Review in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Aquablation/AquaBeam Waterjet Therapy for Benign Prostatic Hyperplasia: Three-Year Functional and Ejaculatory Outcomes in a Multicenter Real-World Italian Cohort.Lower urinary tract symptoms · 2026Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Benign prostatic hyperplasia (BPH) is more prevalent with increasing age, leading to presentations with lower urinary tract symptoms (LUTS). Transurethral resection of the prostate (TURP) remains the gold standard surgical treatment, but its limitations and complications have prompted the development of minimally invasive surgeries. This review evaluates the efficacy and safety of holmium laser enucleation of the prostate (HoLEP), water vapor therapy (Rezum), and robotic water-jet resection (Aquablation) in benign prostate surgery. A narrative review was conducted using PubMed and Google Scholar to identify current literature published between January 2000 and August 2025. Meta-analyses and randomized controlled trials (RCTs) were preferred, but all levels of evidence were considered for this article. Search terms included "benign prostatic hyperplasia", "BPH", "Rezum", "HoLEP", and "Aquablation". These emerging minimally invasive prostate surgeries show promising outcomes and have a role to play, depending on patient choices, surgical expertise, and anatomical factors. HoLEP provides good long-term outcomes and is non-inferior to TURP outcomes in International Prostate Symptom Score (IPSS) and maximum urinary flow rate (Qmax), particularly in larger prostates. Rezum can be performed in an outpatient setting and is effective in preserving sexual function. Aquablation is also effective in preserving sexual function and is suitable for larger prostates. In conclusion, surgical options for managing BPH are evolving technologies that are increasingly replacing the gold standard TURP. More multicenter RCTs comparing all techniques are required to ensure that the data are representative across all populations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.